Julie Ducharme, MD
Endocrinology, Diabetes & Metabolism · Havre de Grace, MDNPI 1033250048
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Lilly USA, LLC accounts for 71.8% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2019 at $17,010 and has fallen 94.8% since, to $879 in 2025.
Across 423 payments — averaging $54.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$17K
- Novo Nordisk$937
- AbbVie$771
- Amgen$656
- Sanofi-aventis U.S. LLC$565
- Corcept Therapeutics$334
- plus $3K from 36 others
What the payments were for
- Consulting fees$2,60011%
- Speaking & faculty fees$11,42550%
- Travel & lodging$1,1135%
- Food & beverage$7,86034%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 76 | $16,546 |
| Novo Nordisk | 68 | $937 |
| AbbVie | 48 | $771 |
| Amgen(2 entities) | 29 | $656 |
| Sanofi-aventis U.S. LLC | 31 | $565 |
| Corcept Therapeutics | 19 | $334 |
| Radius Health, Inc. | 12 | $319 |
| AstraZeneca(2 entities) | 14 | $252 |
| Amneal Pharmaceuticals LLC | 18 | $238 |
| IBSA Pharma Inc. | 10 | $215 |
| Insulet Corporation | 7 | $187 |
| Medtronic(2 entities) | 9 | $163 |
| Abbott | 9 | $162 |
| Baxter Healthcare | 1 | $149 |
| Antares Pharma, Inc. | 7 | $139 |
| Cequr Corporation | 2 | $117 |
| Amarin Pharma, Inc. | 5 | $110 |
| Merck | 7 | $108 |
| Tandem Diabetes Care, Inc. | 6 | $105 |
| Novartis | 5 | $93 |
| Xeris Pharmaceuticals, Inc. | 4 | $89 |
| Dexcom, Inc. | 5 | $86 |
| BD | 3 | $81 |
| Pfizer | 3 | $64 |
| Boehringer Ingelheim | 3 | $60 |
| Embecta Corp. | 2 | $56 |
| Johnson & Johnson | 2 | $46 |
| Bayer | 2 | $43 |
| Mannkind Corporation | 2 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $40 |
| Lifescan, Inc. | 2 | $39 |
| BETA Bionics, Inc. | 1 | $35 |
| Sequel Med Tech, LLC | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Senseonics, Incorporated | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Clarus Therapeutics Inc. | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Companion Medical, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Intuity Medical Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,047 in reported general payments places this provider in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 181 | $371,404 |
| TrulicityDulaglutide | 137 | $238,600 |
| JardianceEmpagliflozin | 171 | $217,867 |
| MounjaroTirzepatide | 53 | $99,665 |
| FarxigaDapagliflozin Propanediol | 77 | $94,701 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 33 | $88,803 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 61 | $84,540 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $64,868 |
| JanuviaSitagliptin Phosphate | 47 | $57,626 |
| RybelsusSemaglutide | 23 | $56,949 |
| Humalog Kwikpen U-200Insulin Lispro | 29 | $54,493 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 26 | $53,620 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $43,763 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 36 | $40,522 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $33,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $937 | $494,325261 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $16,546 | $346,637210 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $60 | $241,740185 claims |
| MerckJanuvia, Janumet Xr | $108 | $98,14783 claims |
| AstraZenecaFarxiga | $252 | $94,70177 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $565 | $84,54061 claims |
| AbbVieSynthroid | $771 | $23,601225 claims |
| IBSA Pharma Inc.Tirosint | $215 | $6,97820 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $238 | $3,854290 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Havre de Grace
- Shristi NeupaneHavre de Grace$5K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.